Shares of the WuXi family of biotech and research companies fell sharply after a U.S. bill targeting certain Chinese biotechnology providers got the green light to go to the Senate floor, reigniting worries about potential U.S. sanctions.
Shares of the WuXi family of biotech and research companies fell sharply after a U.S. bill targeting certain Chinese biotechnology providers got the green light to go to the Senate floor, reigniting worries about potential U.S. sanctions.